TriSalus Life Sciences heads into its third-quarter report with a credibility problem that only revenue can fix. Management has held its full-year sales outlook at $54 million to $57 million since cutting it from $60 million to $62 million earlier this year. Analysts plainly do not believe the reaffirmed range, and the stock has slumped since the last report. Thursday-morning-style suspense is not needed here. The math is simple and unforgiving: after $20.3 million in first-half revenue, TriSalus must generate roughly $34 million to $37 million in the back half to hit its own targets.

Wall Street expects third-quarter revenue of about $14.0 million, up 21% from a year ago and roughly 23% above the $11.4 million posted in the second quarter. The consensus loss is $0.14 per share, a sharp improvement from the $0.96 loss a year earlier and slightly better than last quarter's $0.16. The more telling number is the full-year consensus of $52.4 million, which sits below the bottom of management's range. If the company merely meets the third-quarter estimate, it would still need a fourth quarter near $20 million just to reach the low end of guidance. That would be about 50% above the $13.2 million it booked in the fourth quarter of 2025. A third-quarter print meaningfully above $14 million would shrink that gap and make the guidance look achievable. A shortfall would make a second cut hard to avoid.

The operating story management told last quarter was one of a disrupted sales-force realignment giving way to execution. Second-quarter revenue landed exactly on the internal plan, the reps were two quarters into their new territories, and the company won a CMS G-code that extends TriNav reimbursement into office-based labs. That code arrived in July, so this is the first quarter in which it could show up in orders. Early evidence of TriNav pull-through in office-based settings would validate the claim that the code can accelerate adoption. The same goes for any commentary tying it to uterine artery embolization. Silence on that front, or a vague promise of future benefit, would suggest the catalyst is slower to monetize than hoped.

Costs deserve equal attention. Gross margin has crept up to 86.8% on lower TriNav unit costs, and holding that level is table stakes. The bigger test is spending. The adjusted EBITDA loss widened from under $1 million in late 2025 to $7.1 million in the second quarter as sales and marketing expense rose to $11.4 million. Management said that line would decline sequentially in the second half as expansion costs roll off. Lower selling expense alongside rising revenue would show the first signs of operating leverage. With $46.3 million in cash at midyear, the burn rate matters more than the per-share loss.

Several loose ends could color the tone. TriNav Advance clearance has slipped past its FDA review goal and was already pulled from second-half revenue assumptions, so a clearance would be upside rather than a requirement. Investors will also want clarity on the pancreatic program and Nelotolimab, which management said it was re-evaluating after changes in the treatment landscape. Updates on the clinical pipeline round out the list, including PETR publication timing and enrollment at the Stanford PRESSURE study.

Market sentiment has soured considerably. Bearish readings jumped to nearly 80% from about a third heading into the prior report. The shares have fallen 26.5% since then, trailing the S&P 500 by 24 points, and at $3.63 they sit well below the 200-day average of $4.40, just above the post-earnings low of $3.52. That pessimism lowers the bar somewhat, but it also signals that investors want proof rather than promises. The report hinges on whether third-quarter revenue and fourth-quarter commentary show a credible path to at least $54 million. If they do, the rebuild narrative survives. If not, the reaffirmed guidance becomes the next thing to fall.